⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
TGTX News
TG Therapeutics, Inc.
TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting
globenewswire.com
TGTX
Multiple Sclerosis Market Competitive Landscape Report 2026: Comprehensive Insights on Over 60 Companies and 75 Drugs by Product Type, Development Stage, Administration Route, and Molecule Type
globenewswire.com
SNY
IMUX
TLSA
BIIB
BMY
TGTX
Form 8-K
sec.gov
TGTX
TG Therapeutics Secures an Additional $500 Million in Non-Dilutive Capital from Blue Owl and Expands Share Repurchase Program to $300 Million
globenewswire.com
TGTX
CD19 Inhibitors Market to Witness Significant Expansion During the Forecast Period (2025-2034) as Autoimmune and Oncology Pipelines Accelerate | DelveInsight
prnewswire.com
GILD
INCY
BIIB
NVS
AMGN
JNJ
ABBV
BMY
AZN
MRK
PFE
TGTX
XNCR
CABA
IMUX
ZNTL
GLPG
CLNN
AUTL
Data Published in Neurology and Therapy Demonstrate Significant Reductions in Relapse and MRI Activity with BRIUMVI® in People with Highly Active Relapsing Multiple Sclerosis
globenewswire.com
TGTX
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting
globenewswire.com
TGTX
Tangram Therapeutics annonce l’administration de la première dose à un participant dans le cadre de l’essai RESTORE-MASH de phase I/II portant sur le TGM-312, un nouveau médicament expérimental à base d’ARNi
globenewswire.com
TGTX
Precision BioSciences Receives $7.5M in Proceeds from TG Therapeutics for Azer-cel Clinical Milestone in Multiple Sclerosis
businesswire.com
DTIL
TGTX
Precision BioSciences Receives $7.5M in Proceeds from TG Therapeutics for Azer-cel Clinical Milestone in Multiple Sclerosis
businesswire.com
TGTX
DTIL